top of page

CureLab Veterinary

CureLab Veterinary Common Stock 1
P62 plasmid technology poised to revolutionize cancer treatment in dogs and cats


Crowd Score
There is a newer open investment round for this company - click here to view
Our take:
If the maximum offering is raised, more than 40% will go towards compensation for managers. The technology is licensed from a different company with the same management. In the press release announcing this new company, the company said they expected to be profitable in 3 years, but the crowdfunding campaign says that it doesn't expect sales to start for at least 24-36 months.

Thanks, catch you soon!

Sign up to receive weekly deal alerts and top news

Round Performance

Amount Raised


Average Investment


Average Per Day


# of Investors


Investors vs. Capital Raised

Investment Type

Common Stock

Round Valuation


Minimum Investment


Price Per Share


Investment Details

Early Bird Perks

Perk description
Perk level (dollars)
Perk level (days)

No early bird perks for this round!

Screen Shot 2020-07-15 at 12.01.28

View early bird perks, company financials, valuation methods, and more

Similar Investments

bottom of page